文献速递肺结节与肺癌

AIM-HIGH:14基因表达谱识别IA-IIA期非鳞非小细胞肺癌分子高风险患者辅助化疗的随机III期试验

Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2025-06-24

AIM-HIGH是一项在法国、德国和美国45个中心开展的随机III期试验,评估铂类辅助化疗在14基因表达谱判定的IA-IIA期分子高风险非鳞NSCLC患者中的疗效与安全性。

要点

  • 14基因表达谱可识别IA-IIA期非鳞NSCLC分子高风险患者。
  • 中期分析中辅助化疗组24个月无病生存率96%优于观察组79%。

核心结论

  • 14基因表达谱识别的分子高风险IA-IIA期非鳞NSCLC患者可从铂类辅助化疗中获益。

研究设计与样本

  • 国际、随机、III期试验,在法国、德国和美国45个中心开展。
  • 入组年龄≥18岁、ECOG 0-1、IA-IIA期非鳞NSCLC且有足够肿瘤样本的患者,经14基因表达谱风险分层。
  • 分子高风险(高风险或中等风险评分)患者按1:1随机分配至4周期铂类辅助化疗或观察,按年龄、性别和肿瘤大小≥4 cm分层。
  • 主要终点为改良意向治疗人群的48个月无病生存率,本次预设中期分析主要终点为24个月无病生存率。
  • 共449例患者入组风险分层,236例分子高风险患者随机分配(化疗124例,观察112例);中期分析时改良意向治疗人群可评估87例(化疗组)和107例(观察组)。

主要发现

  • 化疗组24个月无病生存率为96%(95%CI 92-100),观察组为79%(95%CI 70-90)。
  • 中期分析时改良意向治疗人群200例患者中6例(3%)死亡。
  • 化疗组和观察组分别有48例(55%)和58例(54%)为IA期,34例(39%)和44例(41%)为IB期,5例(6%)和5例(5%)为IIA期。

关键数值与推荐

  • 分子高风险定义为14基因表达谱高风险或中等风险评分。
  • 辅助化疗为4周期铂类方案,采用当地机构标准治疗 regimen。
  • 主要终点48个月无病生存率(改良意向治疗人群),中期分析报告24个月无病生存率。

临床怎么用

  • 对于IA-IIA期非鳞NSCLC,可考虑使用14基因表达谱识别分子高风险患者以指导辅助化疗决策。
  • 分子高风险患者接受铂类辅助化疗可能显著改善无病生存。

局限性

  • 随访时间较短,24个月无病生存率为中期分析结果。
  • 试验已停止入组,最终分析需等待成熟数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA-IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB and IIA, but suggest criteria that have not been validated to predict benefit. A previously validated, CLIA-certified 14-gene expression profile has identified patients with high-risk non-squamous NSCLC tumours in stages IA-IIA who benefitted from adjuvant chemotherapy in a non-randomised prospective study. In this prespecified interim analysis, we aimed to assess the efficacy and safety of platinum-based adjuvant chemotherapy in patients with stage IA-IIA molecular high-risk non-squamous NSCLC in a randomised trial. METHODS: AIM-HIGH, a randomised, phase 3 trial, was done at 45 centres in France, Germany, and the USA. Patients aged 18 years or older with stage IA-IIA non-squamous NSCLC, an adequate tumour sample, and an Eastern Cooperative Oncology Group performance status of 0-1 underwent risk stratification with the 14-gene assay. Patients with a molecular high risk, defined as those receiving a high-risk or an intermediate-risk score, were randomly assigned (1:1) to four cycles of platinum-based adjuvant chemotherapy (using local institutional standard of care regimens) or observation. Randomisation was stratified according to age, sex, and tumour size of 4 cm or more. The primary outcomes for the study and for this prespecified interim analysis were 48-month and 24-month disease-free survival, respectively, in the modified intention-to-treat (mITT) population, which was defined as randomly assigned patients who continued to meet eligibility criteria either at chemotherapy initiation or at random assignment to observation; an early interim analysis was prespecified to detect a large difference between groups. This trial is registered at ClinicalTrials.gov, NCT01817192, and is closed to enrolment. FINDINGS: Between Sept 11, 2020, and Feb 7, 2025, 449 patients were enrolled and underwent risk stratification. 236 patients with molecular high risk were randomly assigned to chemotherapy (n=124) or observation (n=112). At the time of the prespecified interim analysis, 87 patients were evaluable in the mITT population (47 [54%] males and 40 [46%] females; median age 63 years [IQR 52-74]) in the chemotherapy group and 107 (58 [54%] males and 49 [46%] females; 66 years [56-76]) in the observation group. 48 (55%) patients in the chemotherapy group and 58 (54%) patients in the observation group had stage IA disease; 34 (39%) and 44 (41%), respectively, had stage IB disease, and five (6%) and five (5%), respectively, had stage IIA disease. Six (3%) of 200 patients in the mITT population had died at the time of the interim analysis. 24-month disease-free survival was 96% (95% CI 92-100) with adjuvant chemotherapy versus 79% (70-90) with observation (hazard ratio 0·22 [0·06-0·76]; p=0·0087). INTERPRETATION: The 14-gene assay identified patients with molecular high risk who benefitted from adjuvant chemotherapy. Use of the assay to determine eligibility for adjuvant therapy in stage IA-IIA non-squamous NSCLC has the potential to substantially improve otherwise persistently poor outcomes. FUNDING: Razor Genomics.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Spigel DR, Westeel V, Anderson IC, et al. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. Lancet Respir Med. 2025. PMID: 40578381. doi:10.1016/S2213-2600(25)00213-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。